Transforming growth factor-β in T-cell biology

Nature Reviews Immunology

Volumn 2, Issue 1, 2002, Pages 46-53

  Gorelik, Leonid ^a   Flavell, Richard A ^b  

^a BIOGEN   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CLASS II TRANSACTIVATOR PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; T LYMPHOCYTE RECEPTOR; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GATA; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; AUTOANTIGEN;

ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CELL SELECTION; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; ENTERITIS; EPIGENETICS; HELPER CELL; HEREDITY; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; LYMPHOCYTE DIFFERENTIATION; MODEL; NONHUMAN; POSITIVE SELECTION; PRIORITY JOURNAL; PROTEIN FAMILY; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE DIFFERENTIATION; TATA BOX; TUMOR IMMUNITY; ANIMAL; AUTOIMMUNITY; BIOLOGICAL MODEL; CELL DIFFERENTIATION; CYTOLOGY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; NEOPLASM;

ANIMALS; ANTIGEN-PRESENTING CELLS; APOPTOSIS; AUTOANTIGENS; AUTOIMMUNITY; CELL DIFFERENTIATION; HOMEOSTASIS; HUMANS; LYMPHOCYTE ACTIVATION; MODELS, IMMUNOLOGICAL; NEOPLASMS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TRANSFORMING GROWTH FACTOR BETA;

EID: 0036372440     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri704     Document Type: Review

References (75)

1. Shull, M. M. et al. Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature 359, 693-699 (1992).
2. Kulkarni, A. B. et al. Transforming growth factor β1 null mutation in mice causes excessive inflammatory response and early death Proc. Natl Acad. Sci USA 90, 770-774 (1993).
3. Kaartinen, V. et al. Abnormal lung development and cleft palate in mice lacking TGF-β3 indicates defects of epithelial-mesenchymal interaction. Nature Genet. 11, 415-421 (1995).
4. Proetzel, G. et al. Transforming growth factor-β3 is required for secondary palate fusion. Nature Genet. 11, 409-414 (1995).
5. Sanford, L. P. et al. TGFβ2 knockout mice have multiple developmental defects that are non-overlapping with other TGFβ knockout phenotypes. Development 124, 2659-2670 (1997).
6. Schluesener, H., Jung, S. & Salvetti, M. Susceptibility and resistance of human autoimmune T cell activation to the immunoregulatory effects of transforming growth factor (TGF)β1, β2, and β1.2. J. Neuroimmunol. 28, 271-276 (1990).
7. Stoeck, M. et al. Comparison of the immunosuppressive properties of milk growth factor and transforming growth factors β1 and β2. J. Immunol. 143, 3258-3265 (1989).
8. Kehrl, J. H. et al. Production of transforming growth factor β by human T lymphocytes and its potential role in the regulation of T cell growth. J. Exp. Med. 163, 1037-1050 (1986). First demonstration of the important role of TGF-β in T-cell regulation.
9. Brabletz, T. et al. Transforming growth factor β and cyclosporin A inhibit the inducible activity of the interleukin-2 gene in T cells through a noncanonical octamer-binding site. Mol. Cell. Biol. 13, 1155-1162 (1993).
10. Hannon, G. J. & Beach, D. p151NK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 371, 257-261 (1994).
11. Datto, M. B. et al. Transforming growth factor β induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc. Natl Acad. Sci. USA 92, 5545-5549 (1995).
12. Polyak, K. et al. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev. 8, 9-22 (1994).
13. Coffey, R. J. Jr. et al. Selective inhibition of growth-related gene expression in murine keratinocytes by transforming growth factor β. Mol. Cell. Biol. 8, 3088-3093 (1988).
14. H2 cytokine secretion phenotype. J. Immunol. 153, 3514-3522 (1994).
15. Swain, S. L., Huston, G., Tonkonogy, S. & Weinberg, A. Transforming growth factor-β and IL-4 cause helper T cell precursors to develop into distinct effector helper cells that differ in lymphokine secretion pattern and cell surface phenotype. J. Immunol. 147, 2991-3000 (1991).
16. Ranges, G. E., Figari, I. S. Espevik, T. & Palladino, M. A. Jr. Inhibition of cytotoxic T cell development by transforming growth factor β and reversal by recombinant tumor necrosis factor α. J. Exp. Med. 166, 991-998 (1987).
17. + T cells isolated from different mouse strains. J. Immunol. 155, 3788-3793 (1995).
18. Lingnau, K. et al. IL-4 in combination with TGF-β favors an alternative pathway of T.1 development independent of IL-12. J. Immunol. 161, 4709-4718 (1998).
19. Hayashi, H. et al. The MAD-related protein Smad7 associates with the TGFβ receptor and functions as an antagonist of TGFβ signaling. Cell 89, 1165-1173 (1997).
20. Nakao, A. et al. Identification of Smad7, a TGFβ-inducible antagonist of TGF-β signalling. Nature 389, 631-635 (1997).
21. Ulloa, L., Doody, J. & Massague, J. Inhibition of transforming growth factor-β/SMAD signalling by the interferon-γ/STAT pathway. Nature 397, 710-713 (1999).
22. Tau, G. Z. et al. Interferon-γ signaling alters the function of T helper type 1 cells. J. Exp. Med. 192, 977-986 (2000).
23. Kitani, A. et al. Treatment of experimental (trinitrobenzene sulfonic acid) colitis by intranasal administration of transforming growth factor (TGF)-β1 plasmid: TGF-β1-mediated suppression of T helper cell type 1 response occurs by interleukin (IL)-10 induction and IL-12 receptor β2 chain downregulation. J. Exp. Med. 192, 41-52 (2000).
24. H2 T cells. Eur. J. Immunol. 30, 2101-2111 (2000).
25. H type 2 development through inhibition of GATA-3 expression. J. Immunol. 166, 4773-4777 (2000).
26. H2 development and results in decreased IL-4-induced STAT6 activation and GATA-3 expression. Eur. Immunol. 30, 2639-2649 (2000).
27. H2 differentiation.
28. H cells. J. Immunol. 161, 1664-1670 (1998).
29. H1 lineage commitment. Cell 100, 655-669 (2000). Cloning of a new T-box protein, T-bet, and demonstration of the important role it has in IFN-γ production.
30. H1 development.
31. Xanthos, J. B., Kofron, M., Wylie, C. & Heaeman, J. Maternal VegT is the initiator of a molecular network specifying endoderm in Xenopus laevis. Development 128, 167-180 (2001).
32. Weber, H., Symes, C. E., Walmsley, M. E., Rodaway, A. R. & Patient, R. K. A role for GATA5 in Xenopus endoderm specification. Development 127, 4345-4360 (2000).
33. Nikaido, M., Tada, M., Takeda, H., Kuroiwa, A. & Ueno, N. In vivo analysis using variants of zebrafish BMPR-IA: range of action and involvement of BMP in ectoderm patterning. Development 126, 181-190 (1999).
34. Kimelman, D. & Griffin, K. J. Vertebrate mesendoderm induction and patterning. Curr. Opin. Genet. Dev. 10, 350-356 (2000).
35. Sallusto, F., Lenig, D., Forster, R., Lipp, M. & Lanzavecchia, A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401, 708-712 (1999).
36. Zhang, X., Giangreco, L., Broome, H. E., Dargan, C. M. & Swain, S. L. Control of CD4 effector fate: transforming growth factor β1 and interleukin 2 synergize to prevent apoptosis and promote effector expansion. J. Exp. Med. 182, 699-709 (1995).
37. Genestier, L., Kasibhatla, S., Brunner, T. & Green, D. R. Transforming growth factor β1 inhibits Fas ligand expression and subsequent activation-induced cell death in T cells via downregulation of c-Myc. J. Exp. Med. 189, 231-239 (1999).
38. Gorelik, L. & Flavell, R. A. Abrogation of TGFβ signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 12, 171-181 (2000).
39. Geiser, A. G. et al. Transforming growth factor β1 (TGF-β1) controls expression of major histocompatibility genes in the postnatal mouse: aberrant histocompatibility antigen expression in the pathogenesis of the TGF-β1 null mouse phenotype. Proc. Natl Acad. Sci. USA 90, 9944-9948 (1993).
40. Lucas, P. J., Kim, S. J., Melby, S. J. & Gress, R. E. Disruption of T cell homeostasis in mice expressing a T cell-specific dominant negative transforming growth factor βII receptor. J. Exp. Med. 191, 1187-1196 (2000).
41. Nakao, A. et al. Blockade of transforming growth factor beta/Smad signaling in T cells by overexpression of Smad7 enhances antigen-induced airway inflammation and airway reactivity. J. Exp. Med. 192, 151-158 (2000).
42. Vasquez, N. J., Kaye, J. & Hedrick, S. M. In vivo and in vitro clonal deletion of double-positive thymocytes. J. Exp. Med. 175, 1307-1316 (1992).
43. Mombaerts, P. et al. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 68, 869-877 (1992).
44. Kullberg, M. C. et al. Helicobacter hepaticus triggers colitis in specific-pathogen-free interleukin-10 (IL-10)-deficient mice through an IL-12-and γ-interferon-dependent mechanism. Infect. Immun. 66, 5157-5166 (1998).
45. Monteleone, G. et al. Blocking Smad7 restores TGF-β1 signaling in chronic inflammatory bowel disease. J. Clin. Invest. 108, 601-609 (2001).
46. Hugot, J. P. et al. Association of NOD2 leucine-rich repeat vadants with susceptibility to Crohn's disease. Nature 411, 599-603 (2001).
47. Ogura, Y. et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411, 603-606 (2001).
48. + regulatory T cells is mediated by cell surface-bound transforming growth factor β. J. Exp. Med. 194, 629-644 (2001).
49. + T cells in the regulation of autoimmunity.
50. +, naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int. Immunol. 10, 1969-1980 (1998).
51. Shevach, E. M. Regulatory T cells in autoimmmunity. Annu. Rev. Immunol. 18, 423-449 (2000).
52. Sakaguchi, S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 101, 455-458 (2000).
53. + T cells. J. Exp. Med. 183, 2669-2674 (1996).
54. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 168, 287-296 (1998).
55. Fadok, V. A. et al. A receptor for phosphatidylserine-specific clearance of apoptotic cells. Nature 405, 85-90 (2000). Cloning of the phosphatidylserine specific receptor and demonstration of its role in the TGF-β production by macrophages in response to apoptotic cells.
56. Gallucci, S., Lolkema, M. & Matzinger, P. Natural adjuvants: endogenous activators of dendritic cells. Nature Med. 5, 1249-1255 (1999).
57. Chen, W., Frank, M. E., Jin, W. & Wahl, S. M. TGF-β released by apoptotic T cells contributes to an immunosuppressive milieu. Immunity 14, 715-725 (2001).
58. Heine, U. I. et al. Localization of transforming growth factor-β1 in mitochondria of murine heart and liver. Cell. Regul. 2, 467-477 (1991).
59. Bogdan, C. & Nathan, C. Modulation of macrophage function by transforming growth factor beta, interleukin-4, and interleukin-10. Ann. NY Acad. Sci. 685, 713-739 (1993).
60. Vodovotz, Y. & Bogdan, C. Control of nitric oxide synthase expression by transforming growth factor-β: implications for homeostasis. Prog. Growth Factor Res. 5, 341-351 (1994).
61. Yamaguchi, Y., Tsumura, H., Miwa, M. & Inaba, K. Contrasting effects of TGF-β1 and TNF-α on the development of dandritic cells from progenitors in mouse bone marrow. Stem Cells 15, 144-153 (1997).
62. Geissmann, F. et al. TGF-β1 prevents the noncognate maturation of human dendritic Langerhans cells J. Immunol. 162, 4567-4575 (1999).
63. Mellman, I. & Steinman, R. M. Dendritic cells: specialized and regulated antigen processing machines. Cell 106, 255-258 (2001).
64. Jin, Y. X. et al. TGF-β1 inhibits protracted-relapsing experimental autoimmune encephalomyelitis by activating dendritic cells. J. Autoimmun. 213-220 (2000).
65. Lee, Y. J. et al. TGF-β suppresses IFN-γ induction of class II MHC gene expression by inhibiting class II transactivator messenger RNA expression. J. Immunol. 158, 2065-2075 (1997).
66. Nandan, D. & Reiner, N. E. TGF-β attenuates the class II transactivator and reveals an accessory pathway of IFN-γ action. J. Immunol. 158, 1095-1101 (1997).
67. Cazac, B. B. & Roes, J. TGF-β receptor controls B cell responsiveness and induction of IgA in vivo. Immunity 13, 443-451 (2000).
68. Pasche, B. Role of transforming growth factor β in cancer. J. Cell. Physiol. 186, 153-168 (2001).
69. Chakravarthy, D., Green, A. R., Green, V. L., Kerin, M. J. & Speirs, V. Expression and secretion of TGF-β isoforms and expression of TGF-β-receptors I, I, and III in normal and neoplastic human breast. Int. J. Oncol. 15, 187-194 (1999).
70. van Roozendaal, C. E. et al. Transforming growth factor β secretion from primary breast cancer fibroblasts. Mol. Cell. Endocrinol. 111, 1-6 (1995).
71. +) T cells established from murine tumor-infiltrating lymphocytes. J. Immunol. 158, 4846-4854 (1997).
72. Seo, N., Tokura, Y., Takigawa, M. & Egawa, K. Depletion of IL-10- and TGF-β-producing regulatory γδ T cells by administering a daunomycin-conjugated specific monoclonal antibody in early tumor lesions augments the activity of CTLs and NK cells. J. Immunol. 163, 242-249 (1999).
73. Won, J. et al. Tumorigenicity of mouse thymoma is suppressed by soluble type II transforming growth factor β receptor therapy. Cancer Res. 59, 1273-1277 (1999).
74. Gorelik, L. & Flavell, R. A. Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells. Nature Med. 7, 1118-1122 (2001).
75. Massagué, J. How cells read TGF-β signals. Nature Rev. Mol. Cell Biol. 1, 169-178 (2000).